These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 27805299)

  • 1. Step-wise loss of antidepressant effectiveness with repeated antidepressant trials in bipolar II depression.
    Amsterdam JD; Lorenzo-Luaces L; DeRubeis RJ
    Bipolar Disord; 2016 Nov; 18(7):563-570. PubMed ID: 27805299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and effectiveness of continuation antidepressant versus mood stabilizer monotherapy for relapse-prevention of bipolar II depression: A randomized, double-blind, parallel-group, prospective study.
    Amsterdam JD; Lorenzo-Luaces L; Soeller I; Li SQ; Mao JJ; DeRubeis RJ
    J Affect Disord; 2015 Oct; 185():31-7. PubMed ID: 26143402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does tachyphylaxis occur after repeated antidepressant exposure in patients with Bipolar II major depressive episode?
    Amsterdam JD; Shults J
    J Affect Disord; 2009 May; 115(1-2):234-40. PubMed ID: 18694599
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increase in pharmacodynamic tolerance after repeated antidepressant trials in treatment-responsive bipolar I depressed subjects: An exploratory study.
    Amsterdam JD; Lorenzo-Luaces L
    Psychiatr Pol; 2018 Dec; 52(6):957-969. PubMed ID: 30659559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapid versus non-rapid cycling bipolar II depression: response to venlafaxine and lithium and hypomanic risk.
    Lorenzo-Luaces L; Amsterdam JD; Soeller I; DeRubeis RJ
    Acta Psychiatr Scand; 2016 Jun; 133(6):459-69. PubMed ID: 26803764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antidepressant discontinuation in bipolar depression: a Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) randomized clinical trial of long-term effectiveness and safety.
    Ghaemi SN; Ostacher MM; El-Mallakh RS; Borrelli D; Baldassano CF; Kelley ME; Filkowski MM; Hennen J; Sachs GS; Goodwin FK; Baldessarini RJ
    J Clin Psychiatry; 2010 Apr; 71(4):372-80. PubMed ID: 20409444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prior Antidepressant Treatment Trials May Predict a Greater Risk of Depressive Relapse During Antidepressant Maintenance Therapy.
    Amsterdam JD; Kim TT
    J Clin Psychopharmacol; 2019; 39(4):344-350. PubMed ID: 31205190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of venlafaxine versus lithium monotherapy on quality of life in bipolar II major depressive disorder: Findings from a double-blind randomized controlled trial.
    Lorenzo-Luaces L; Amsterdam JD
    Psychiatry Res; 2018 Jan; 259():455-459. PubMed ID: 29136600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and bupropion as adjuncts to mood stabilizers.
    Leverich GS; Altshuler LL; Frye MA; Suppes T; McElroy SL; Keck PE; Kupka RW; Denicoff KD; Nolen WA; Grunze H; Martinez MI; Post RM
    Am J Psychiatry; 2006 Feb; 163(2):232-9. PubMed ID: 16449476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rational polypharmacy in the bipolar affective disorders.
    Post RM; Ketter TA; Pazzaglia PJ; Denicoff K; George MS; Callahan A; Leverich G; Frye M
    Epilepsy Res Suppl; 1996; 11():153-80. PubMed ID: 9294735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short-term venlafaxine v. lithium monotherapy for bipolar type II major depressive episodes: effectiveness and mood conversion rate.
    Amsterdam JD; Lorenzo-Luaces L; Soeller I; Li SQ; Mao JJ; DeRubeis RJ
    Br J Psychiatry; 2016 Apr; 208(4):359-65. PubMed ID: 26892848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Residual anxiety may be associated with depressive relapse during continuation therapy of bipolar II depression.
    Lorenzo-Luaces L; Amsterdam JD; DeRubeis RJ
    J Affect Disord; 2018 Feb; 227():379-383. PubMed ID: 29149756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of antidepressant discontinuation versus antidepressant continuation on 1-year risk for relapse of bipolar depression: a retrospective chart review.
    Altshuler L; Kiriakos L; Calcagno J; Goodman R; Gitlin M; Frye M; Mintz J
    J Clin Psychiatry; 2001 Aug; 62(8):612-6. PubMed ID: 11561933
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of antidepressant discontinuation after acute bipolar depression remission on rates of depressive relapse at 1-year follow-up.
    Altshuler L; Suppes T; Black D; Nolen WA; Keck PE; Frye MA; McElroy S; Kupka R; Grunze H; Walden J; Leverich G; Denicoff K; Luckenbaugh D; Post R
    Am J Psychiatry; 2003 Jul; 160(7):1252-62. PubMed ID: 12832239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of treatment outcome using two definitions of rapid cycling in subjects with bipolar II disorder.
    Amsterdam JD; Lorenzo-Luaces L; DeRubeis RJ
    Bipolar Disord; 2017 Feb; 19(1):6-12. PubMed ID: 28160351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of antidepressant continuation after acute positive or partial treatment response for bipolar depression: a blinded, randomized study.
    Altshuler LL; Post RM; Hellemann G; Leverich GS; Nolen WA; Frye MA; Keck PE; Kupka RW; Grunze H; McElroy SL; Sugar CA; Suppes T
    J Clin Psychiatry; 2009 Apr; 70(4):450-7. PubMed ID: 19358785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Venlafaxine versus lithium monotherapy of rapid and non-rapid cycling patients with bipolar II major depressive episode: a randomized, parallel group, open-label trial.
    Amsterdam JD; Wang CH; Shwarz M; Shults J
    J Affect Disord; 2009 Jan; 112(1-3):219-30. PubMed ID: 18486235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of short-term venlafaxine versus lithium monotherapy for bipolar II major depressive episode: a randomized open-label study.
    Amsterdam JD; Shults J
    J Clin Psychopharmacol; 2008 Apr; 28(2):171-81. PubMed ID: 18344727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Augmentation of antidepressants with unsaturated fatty acids omega-3 in drug-resistant depression].
    Krawczyk K; Rybakowski J
    Psychiatr Pol; 2012; 46(4):585-98. PubMed ID: 23214161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mood stabilizer augmentation in apparently "unipolar" MDD: predictors of response in the naturalistic French national EPIDEP study.
    Hantouche EG; Akiskal HS; Lancrenon S; Chatenêt-Duchêne L
    J Affect Disord; 2005 Feb; 84(2-3):243-9. PubMed ID: 15708422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.